Drugs / TLC590
TLC590
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03591146 | Jul 2018 → Jan 2019 | — | Taiwan Liposome Company | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06574269 | Sep 2024 → Jul 2026 overdue | — | TLC Biopharmaceuticals, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT03838133 | Mar 2019 → Mar 2020 | toe, misshapen | Taiwan Liposome Company | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05161637 | Apr → Dec 2025 | — | Taiwan Liposome Company | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07222748 | Nov 2025 → Jun 2026 overdue | — | TLC Biopharmaceuticals, Inc. | Active not recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-07-30 | TLC Biopharmaceuticals, Inc. | TLC BioSciences Completes Last Patient Visit in Phase 3 Trial of TLC590 for Postsurgical Pain tlcbio.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TLC590 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05161637 ↗ |
| Known as | Ropivacaine | “TLC590 (Ropivacaine Extended-Release Injectable Suspension)” NCT07222748 ↗ |
| Known as | TLC590 (Ropivacaine Extended-Release Injectable Suspension) | “TLC590 (Ropivacaine Extended-Release Injectable Suspension)” NCT06574269 ↗ |
| Known as | TLC590 (Ropivacaine Liposome Injectable Suspension) | “TLC590 (Ropivacaine Liposome Injectable Suspension)” NCT03838133 ↗1“TLC590 (Ropivacaine Liposome Injectable Suspension)” NCT03591146 ↗ |
| Route | Other | “single infiltrative local administration” NCT03591146 ↗ |